| Metric | Value ($ M) |
|---|---|
| Revenue | 2.00 |
| Total Income | 2.00 |
| Expenditure | 33.74 |
| PBT | -38.73 |
| Net Profit | -38.73 |
| OPM | — |
| NPM | — |
| EPS | -2.46 |
Inhibrx Biosciences Reports Q3 2026 Financial Results
14 Nov 2026 · 14 Nov, 2:44 am
Summary
Inhibrx Biosciences reported its financial results for the third quarter of 2026, recognizing $2.0 million in revenue from a license agreement with Pfizer, compared to no revenue in the prior year quarter. Research and development expenses decreased to $26.0 million, while general and administrative expenses rose to $7.8 million due to pre-commercialization activities. The company reported a net loss of $38.7 million, or $2.46 per share, an increase from the $35.3 million net loss in Q3 2025. As of September 30, 2026, Inhibrx held $199.5 million in cash and cash equivalents.
Key Highlights
- 1
Inhibrx Biosciences recognized $2.0 million of revenue during the third quarter of 2026 under a license agreement with Pfizer, Inc.
- 2
The Company did not recognize any revenue during the third quarter of 2025.
- 3
Research and development expenses were $26.0 million for the third quarter of 2026, a decrease from $28.5 million in the prior year period.
- 4
General and administrative expenses increased to $7.8 million during the third quarter of 2026, compared to $5.3 million during the third quarter of 2025.
- 5
Total other expense increased to $7.0 million during the third quarter of 2026, primarily due to higher interest expense on the Company’s outstanding loan balance.
- 6
Net loss was $38.7 million during the third quarter of 2026, or $2.46 per share, basic and diluted, compared to a net loss of $35.3 million, or $2.28 per share, in the prior year period.
- 7
As of September 30, 2026, the Company had cash and cash equivalents of $199.5 million.
Informational and educational content only. Not investment advice.